SRPT Duchenne Drug trial hits 5 year mark, page-34

And yes. I agree on 2 points. One is that they gathering that safety data so future trials and future standard treatment will be on strength of 500 or more of PBT2 compound. They stated few times 250 strength was meaningless and waste of time. The other point I also believe, Mr Kempler is not fussed with sp performance atm (no need for any funds atm for any trials) plus He must be very confident the share price will recover in a blink with positive news flow so the shareholders will be pacified and money will be easily obtainable for the next leg up in development of our treatments. Still, it is all VERY frustrating. Most frustrating holding to hold.